98%
921
2 minutes
20
We assessed whether single nucleotide polymorphism rs1042615 of the vasopressin V1a receptor altered the indices of lifestyle-related diseases in middle-aged and older people (mean+/-SD: 64+/-7 years), and, if so, whether it also altered the effects of interval walking training (IWT). CC, CT, and TT carriers of rs1042615 (42, 118, and 64 men, respectively; 113, 263, and 154 women, respectively) performed IWT. We included 5 sets of 3-minute fast walking at > or =70% peak aerobic capacity for walking and 3-minute slow walking at 40% peak aerobic capacity per day for > or =4 days per week for 5 months. Before IWT, the body mass index and diastolic blood pressure (DBP) for men were 25.1+/-0.3 kg/m(2) (mean+/-SE) and 84+/-1 mm Hg in TT, higher than the 23.6+/-0.4 kg/m(2) and 78+/-1 mm Hg in CC, respectively (P<0.01), differences that disappeared after IWT despite similar training achievement between groups (P>0.6). After IWT, body mass index and DBP decreased in TT (-0.9+/-0.1 kg/m(2) and -5+/-1 mm Hg, respectively), more than in CC (-0.5+/-0.1 kg/m(2) and 1+/-1 mm Hg, respectively; P<0.05), with a greater decrease in low-density lipoprotein cholesterol in TT than CC carriers (P<0.01). The decreases in DBP and low-density lipoprotein cholesterol were still greater in TT carriers even after adjustment for their pretraining values. On the other hand, for women, these parameters before IWT and their changes after IWT were similar among CC, CT, and TT carriers. Thus, polymorphism rs1042615 of the V1a receptor altered body mass index and DBP in middle-aged and older men and the training-induced responses of DBP and low-density lipoprotein cholesterol, whereas women did not show any of these responses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.147728 | DOI Listing |
Eur J Heart Fail
August 2025
INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy, F-CRIN INI-CR, Université de Lorraine, Nancy, France.
Aims: Balanced dual V1a/ V2 vasopressin receptor antagonism may offer potential advantages as an adjunctive and/or a replacement therapy to loop diuretic therapy.
Methods And Results: AVANTI was a double-blind, randomized trial in patients hospitalized with heart failure and residual congestion. In Part A, patients received pecavaptan or placebo as adjunctive therapy to standard of care for 30 days.
ACS Med Chem Lett
June 2025
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
This patent application discloses a series of l,3-dihydro-2-indol-2-one derivatives targeting the vasopressin 1b receptor (V) or both the V and V receptors, as represented by Formula I. These vasopressin receptor antagonists exhibit significant therapeutic potential, particularly for the treatment of depression or anxiety, and hold promises for benefiting patients with reduced dosing frequency.
View Article and Find Full Text PDFGen Comp Endocrinol
July 2025
Institute of Agricultural and Life Sciences, Academic Assembly, Shimane University, 1060 Nishikawatsu, Matsue, Shimane 690-8504, Japan. Electronic address:
Vasopressin (VP) and its non-mammalian homolog vasotocin (VT) are secreted from the posterior pituitary to control various physiological phenomena via G protein-coupled receptors. The six known subtypes of VP/VT receptor family (V1a/bR and V2a/b/c/dR) originate from a single ancestral molecule, that most likely coupled with Gα and used Ca for signaling. However, among the current VP/VT receptors, V2aR predominantly couples with Gα and increases intracellular cAMP levels.
View Article and Find Full Text PDFPflugers Arch
July 2025
Laboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, A. Pawińskiego Str. 5, 02-106, Warsaw, Poland.
Hyponatremia is the most common electrolyte disturbance in hospitalized patients. Symptoms of hyponatremia include attention deficits and cognitive impairments. The cause of such abnormalities may be disturbances in the regulation of microcirculation.
View Article and Find Full Text PDFAm J Physiol Renal Physiol
July 2025
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States.
Vasopressin plays a major role in the pathogenesis of autosomal dominant polycystic kidney disease (PKD), the fourth leading cause of end-stage kidney disease. The vasopressin V2 receptor (V2R) antagonist tolvaptan is the only approved treatment. The role of vasopressin V1a and V1b receptors (V1aR and V1bR) has not been studied.
View Article and Find Full Text PDF